Renal Impairment, Cardiovascular Disease, and the Short-Term Efficacy and Safety of PCSK9 Targeted by Inclisiran

Mayo Clin Proc. 2020 Jan;95(1):12-14. doi: 10.1016/j.mayocp.2019.11.010.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Cardiovascular Diseases*
  • Humans
  • Proprotein Convertase 9*
  • RNA, Small Interfering

Substances

  • ALN-PCS
  • RNA, Small Interfering
  • PCSK9 protein, human
  • Proprotein Convertase 9